Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling

BackgroundAfatinib is mainly used to treat advanced non-small cell lung cancer, but its therapeutic effect on hepatocellular carcinoma is still unclear.MethodsOver 800 drugs were screened by CCK8 technology and afatinib was found to have a significant inhibitory effect on liver cancer cells. The expression of PDL1 in tumor cells treated with drugs were detected by qRT-PCR and Weston Blot experiments. The effects of afatinib on the growth, migration and invasion of HCC cells were evaluated using wound healing, Transwell, and cell cloning assays. The in vivo effects of afatinib in combination with anti-PD1 were evaluated in C57/BL6J mice with subcutaneous tumorigenesis. Bioinformatics analysis was performed to explore the specific mechanism of afatinib's inhibition of ERBB2 in improving the expression level of PD-L1, which was subsequently verified through experiments.ResultsAfatinib was found to have a significant inhibitory effect on liver cancer cells, as confirmed by in vitro experiments, which demonstrated that it could significantly suppress the growth, invasion and migration of HCC cells. qRT PCR and Weston Blot experiments also showed that Afatinib can enhance the expression of PD-L1 in tumor cells. In addition, in vitro experiments confirmed that afatinib can significantly enhance the immunotherapeutic effect of hepatocellular carcinoma. Afatinib’s ability to increase PD-L1 expression is mediated by STAT3 activation following its action on HCC cells.ConclusionAfatinib enhances PD-L1 expression in tumor cells through the STAT3/PD-L1 pathway. The combination of afatinib and anti-PD1 treatment significantly increases the immunotherapeutic effect of HCC

Iron-nitrogen dual-doped three-dimensional mesoporous carbons for high-activity electrocatalytic oxygen reduction

Iron-nitrogen dual-doped three-dimensional mesoporous carbons for high-activity electrocatalytic oxygen reductio

Mixed-valence gold-porphyrin two-dimensional coordination networks for repurposing of chrysotherapy

Catalytic gold nanomaterials typically exhibit antibacterial properties, albeit significantly weaker than ionic gold in chrysotherapy. The inherent stability of gold nanoparticles prevents the release of gold ions, limiting their ability to achieve efficient antibacterial therapy. To address this limitation, we propose a novel sustained ionic gold release strategy through the construction of a mixed-valence gold-porphyrin coordination network (Au-Por). By adjusting the ratio of Au to porphyrin molecule, an ultrathin two-dimensional Au-Por nanosheet was successfully synthesized, which contains 85.9 % of Au (III). In addition, the remaining gold existed in the form of uniformly distributed ultrasmall nanoclusters on the Au-Por nanosheet. Notably, the Au-Por nanosheet exhibited a sustained release of gold ions. Thus, a multimodal antibacterial therapy was achieved by integrating the direct bactericidal action of ionic gold and lethal reactive oxygen species (ROS) generated through the peroxidase (POD)-like activity of gold nanoclusters and photodynamic therapy (PDT) using porphyrins. The innovative Au-Por exerted broad-spectrum bactericidal activity against both Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus bacteria mediated by bacterial membrane disruption and DNA damage. Moreover, in vivo studies demonstrated the synergistic effect of Au-Por on combating skin wound infections and facilitating wound healing. Comprehensive safety evaluations proved that Au-Por exhibited no hematotoxicity or hepatorenal toxicity, and it also displayed rapid renal clearance after treatment, indicating favorable biocompatibility. The repurposing of chrysotherapy has revolutionized the antibacterial strategy of nanoscale gold, resulting in a dramatic boost in antibacterial activity and valuable insights for designing highly efficient nanoscale antibacterial agents.We thank the National Natural Science Foundation of China (82202309), the Natural Science Foundation of Jiangsu Province (BK20210532), the China Scholarship Council (202008320156), and the Natural Science Research of Jiangsu Higher Education Institutions of China (20KJB430045) for financial support

Three-dimensional interconnected nitrogen-doped mesoporous carbons as active electrode materials for application in electrocatalytic oxygen reduction and supercapacitors

In this paper, a series of nitrogen-doped mesoporous carbons (NMCs) with three-dimensional (3D) interconnected mesopores have been prepared using flour as carbon source, dicyanamide as nitrogen source and colloidal silica as hard template. The optimized material (NMC-4) prepared with the colloidal silica/flour mass ratio of 4 has a high nitrogen doping level of 5.69 at.% and large specific surface area of 995 m(2) g(-1) as well as 3D interconnected mesopores (12.9 nm). As the oxygen reduction reaction (ORR) electrocatalyst among various NMCs, NMC-4 exhibits the superior performance and much better stability and methanol crossover with a four-electron dominant reaction pathway compared to commercial 20 wt% Pt/C. Furthermore, as a supercapacitor (SC) electrode material, NMC-4 exhibits a high specific capacitance of 178.5 F g(-1) at a current density of 0.5 A g(-1) and long cycle life (94.5% capacity retention after 5000 cycles). It also shows a good rate capacity as 76.1% of original specific capacitance remains when the current density increases from 0.5 to 20 A g(-1). The high-performance of NMCs results from the synergetic effects of 3D interconnected mesopores, large surface area, and high N-doping level, enabling fast mass transport and electron transfer during the electrochemical process. This work provides a facile and efficient strategy to heteroatom-doped carbons from extensively available biomass, showing great potentials in electrocatalysis, energy storage, and other applications. (C) 2018 Published by Elsevier Inc

A review of oxygen reduction mechanisms for metal-free carbon-based electrocatalysts

A review of oxygen reduction mechanisms for metal-free carbon-based electrocatalyst

Construction and application of artificial lipoproteins using adiposomes

Lipoproteins are complex particles comprised of a neutral lipid core wrapped with a phospholipid monolayer membrane and apolipoproteins on the membrane, which is closely associated with metabolic diseases. To facilitate the elucidation of its formation and dynamics, as well as its applications, we developed an in vitro system in which adiposomes, consisting of a hydrophobic core encircled by a monolayer-phospholipid membrane, were engineered into artificial lipoproteins (ALPs) by recruiting one or more kinds of apolipoproteins, for example, apolipoprotein (Apo) A-I, ApoE, ApoA-IV, and ApoB. In vitro and in vivo studies demonstrated the stability and biological activity of ALPs derived from adiposomes, which resembles native lipoproteins. Of note, adiposomes bearing ApoE were internalized via clathrin-mediated endocytosis following LDLR binding and were delivered to lysosomes. On the other hand, adiposomes bearing ApoA-IV mimicked the existing form of endogenous ApoA-IV and exhibited significant improvement in glucose tolerance in mice. In addition, the construction process was simple, precise, reproducible, as well as easy to adjust for mass production. With this experimental system, different apolipoproteins can be recruited to build ALPs for some biological goals and potential applications in biomedicine

Apolipoprotein A-IV and its derived peptide, T55−121, improve glycemic control and increase energy expenditure

peer reviewedIt is crucial to understand the glucose control within our bodies. Bariatric/metabolic surgeries, including laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB), provide an avenue for exploring the potential key factors involved in maintaining glucose homeostasis since these surgeries have shown promising results in improving glycemic control among patients with severe type 2 diabetes (T2D). For the first time, a markedly altered population of serum proteins in patients after LSG was discovered and analyzed through proteomics. Apolipoprotein A-IV (apoA-IV) was revealed to be increased dramatically in diabetic obese patients following LSG, and a similar effect was observed in patients after RYGB surgery. Moreover, recombinant apoA-IV protein treatment was proven to enhance insulin secretion in isolated human islets. These results showed that apoA-IV may play a crucial role in glycemic control in humans, potentially through enhancing insulin secretion in human islets. ApoA-IV was further shown to enhance energy expenditure and improve glucose tolerance in diabetic rodents, through stimulating glucose-dependent insulin secretion in pancreatic β cells, partially via Gαs-coupled GPCR/cAMP (G protein-coupled receptor/cyclic adenosine monophosphate) signaling. Furthermore, T55−121, truncated peptide 55−121 of apoA-IV, was discovered to mediate the function of apoA-IV. These collective findings contribute to our understanding of the relationship between apoA-IV and glycemic control, highlighting its potential as a biomarker or therapeutic target in managing and improving glucose regulation